News
-
NOVITÀ
TIF Webinar Fridays Are Back With A New Session on “Heart Disease In Thalassaemia”
This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis…
Read More » -
Clinical News
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia
Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited…
Read More » -
Clinical News
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed…
Read More » -
NOVITÀ
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate…
Read More » -
Member News
-
Clinical News
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced…
Read More » -
NOVITÀ
TIF Develops Mobile Application To Support Patients With Thalassaemia
As part of its enduring efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF will…
Read More » -
NOVITÀ
Coming Up This Week: ”Iron Monitoring in Thalassaemia” Webinar for Patients
Although chronic blood transfusion regimens have added decades to the lives of patients with thalassaemia, clinicians are now faced with…
Read More » -
Member News
Pancyprian Thalassaemia Conference 2020
Τhe Pancyprian Thalassaemia Conference 2020 was successfully held on Saturday, 26 September, to discuss the modern scientific and other developments…
Read More »